Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1988 May 15;44(5):431-6.
doi: 10.1007/BF01940539.

Pharmacodynamic profile of CQP 201-403, a novel 8 alpha-amino-ergoline

E Flückiger  1 , U Briner, B Clark, A Closse, A Enz, P Gull, A Hofmann, R Markstein, L Tolcsvai, H R Wagner
Affiliations
Comparative Study

Pharmacodynamic profile of CQP 201-403, a novel 8 alpha-amino-ergoline

E Flückiger et al. Experientia. .

Abstract

The profile of action in animals of CQP 201-403, a novel 8 alpha-amino-ergoline, is in most aspects that of a very potent dopaminomimetic, both as a prolactin secretion inhibitor, and at the levels of the CNS and the cardiovascular system. Qualitatively CQP 201-403 differs slightly from bromocriptine and apomorphine in its effects on the CNS (no influence on serotonin metabolism in the rat cortex; induction of masculine mounting behavior in rats) and the cardiovascular system of the dog (reflex tachycardia in response to a blood-pressure fall). In man the new compound proved to be highly active in lowering prolactin serum levels and be more potent than bromocriptine (Parlodel).

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. J Neural Transm. 1985;62(3-4):231-48 - PubMed
    1. J Neurochem. 1975 Nov;25(5):653-8 - PubMed
    1. J Neural Transm Suppl. 1983;18:189-204 - PubMed
    1. Science. 1972 Oct 13;178(4057):166-8 - PubMed
    1. Br J Pharmacol. 1978 Mar;62(3):379P - PubMed

Publication types

MeSH terms